GlassScriptPhysician profile
Nagender Mankan
NPI 1396782827
$13,679.30
in general payments reported to CMS, 2019-2025
65 companies · $1,774 in 2025
The $1,774 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,831 · 2020: $754 · 2021: $908 · 2022: $2,046 · 2023: $3,537 · 2024: $1,830 · 2025: $1,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,085.92 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Education | $329.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $1,761.16 | 2023 | Vonjo |
| Astrazeneca Pharmaceuticals LP | $1,145.84 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| Daiichi Sankyo INC. | $1,040.10 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $714.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $668.78 | 2019-2025 | |
| Amgen INC. | $666.93 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Genentech USA, INC. | $605.98 | 2019-2025 | Venclexta, Alecensa, Tecentriq |
| Celgene Corporation | $494.08 | 2019-2025 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $473.97 | 2019-2024 | |
| Janssen Biotech, INC. | $458.10 | 2019-2024 | Rybrevant |
| Seagen INC. | $416.00 | 2019-2023 | Padcev, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $360.14 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Incyte Corporation | $348.27 | 2019-2023 | Monjuvi, Jakafi |
| Exelixis INC. | $343.85 | 2019-2025 | Cabometyx |
| Abbvie INC. | $337.07 | 2019-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $336.65 | 2019-2024 | Padcev, Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $244.38 | 2019-2025 | |
| Gilead Sciences, INC. | $224.58 | 2022-2025 | Trodelvy |
| Eisai INC. | $217.24 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $204.21 | 2019-2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $201.93 | 2021-2024 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $182.24 | 2019-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $168.23 | 2019-2025 | Fruzaqla, Ninlaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.81 | 2019-2022 | |
| Glaxosmithkline, LLC. | $134.60 | 2022-2025 | Zejula, Jemperli, Blenrep |
| Genzyme Corporation | $132.16 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $131.10 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $125.27 | 2022-2024 | Xpovio |
| Caris Mpi, INC. | $115.33 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $115.26 | 2020-2025 | Zoladex |
| Stemline Therapeutics INC. | $78.33 | 2024-2025 | Orserdu |
| Array Biopharma INC | $73.20 | 2020-2025 | Braftovi, Lorbrena, Tukysa |
| Pharmaessentia USA Corporation | $72.15 | 2024-2025 | Besremi |
| Beigene USA, INC. | $64.47 | 2020-2024 | Brukinsa |
| Partner Therapeutics, INC. | $63.17 | 2019 | |
| Mirati Therapeutics, INC. | $61.67 | 2023-2024 | Krazati |
| Epizyme, INC. | $58.13 | 2021-2023 | Tazverik |
| Genmab U.S., INC. | $45.87 | 2024-2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $42.33 | 2019-2020 | |
| Lilly USA, LLC | $41.79 | 2022-2023 | Verzenio, Jaypirca |
| Sobi, INC | $38.16 | 2022-2024 | |
| Puma Biotechnology, INC. | $35.99 | 2019-2024 | |
| Tesaro, INC. | $33.42 | 2019 | |
| Foundation Medicine, INC. | $32.82 | 2023 | Foundationone Liquid Cdx |
| Curium US LLC | $29.63 | 2022 | |
| Recordati_rare_diseases_inc. | $28.22 | 2025 | Enjaymo |
| Heron Therapeutics, INC. | $27.92 | 2019-2020 | |
| Acrotech Biopharma INC. | $26.96 | 2024 | Ryzneuta |
| Invivyd INC | $24.47 | 2025 | Pemgarda |
| Fennec Pharmaceuticals, INC. | $24.28 | 2024 | Pedmark |
| Clovis Oncology, INC. | $22.09 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $21.71 | 2025 | Provenge |
| Sumitomo Pharma America, INC. | $20.21 | 2025 | Orgovyx |
| Nuvation Bio INC. | $19.65 | 2025 | Ibtrozi |
| Macrogenics, INC. | $19.21 | 2022 | |
| Taiho Oncology, INC. | $19.09 | 2019 | |
| Coherus Oncology, INC. | $18.40 | 2020 | |
| Secura Bio, INC. | $18.38 | 2022 | |
| Beone Medicines USA, INC. | $17.93 | 2025 | Tevimbra |
| Kite Pharma, INC. | $17.21 | 2023 | |
| Immunocore Limited | $16.72 | 2025 | Kimmtrak |
| Servier Pharmaceuticals LLC | $16.31 | 2022 | |
| Advanced Accelerator Applications | $16.28 | 2019 | |
| Organon LLC | $15.00 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagender Mankan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.